For immediate distribution
Source: DIAGNOS Inc.

2015.03.18

DIAGNOS Announces First Screening Project in Poland with Globally Leading Pharmaceutical Company

Brossard, Quebec, Canada – March 18, 2015 - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX Venture: ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company that markets a leading ophthalmology product indicated for a variety of ophthalmic complications, including those associated with diabetes, for a screening project in Poland. This project is in conjunction with the same global pharmaceutical company that DIAGNOS works with around the world, including the UAE and India.

According to the International Diabetes Federation, there are over two million people suffering from diabetes in Poland. Following clinical guidelines, 100% of this diabetic population should have their retinas screened yearly, but, currently, only a small proportion of the population is. Resulting from this and other factors, Poland is ranked 25th out of 30 countries in the 2014 Euro Diabetes Index.

"There is no other retina screening program in Poland remotely similar to the one we are launching this month, and, through this program, we hope to improve the availability of care for patients by providing convenient mobile screening locations. DIAGNOS is fortunate enough that, in addition to our pharmaceutical client, we have the support of and are working with the Polish Ophthalmology Society (Polskie Towarzystwo Okulistyczne) and the Polish Diabetes Association (Polskie Stowarzyszenie Diabetyków). Businesses and associations in Poland have been very receptive to what we offer and we have built this project in a way that it can be scaled up quickly," said André Larente, DIAGNOS' President.

About DIAGNOS

DIAGNOS is a publicly traded Canadian corporation with a mission to improve the quality of patients' lives and minimize the economic burden of vision loss. Computer Assisted Retinal Analysis (CARA) is the Company's proprietary tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, the U.S. Food and Drug Administration, and the European Union.

Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:
André Larente, President and CEO
Telephone: 1-877-678-8882 or (450) 678-8882, ext.: 224
alarente@diagnos.ca